en
fi
Orion Group
Menu
Menu
suomeksi
Orion Now
Other websites
Fermion
Orion Pharma Animal Health
Wehale.life
Orion countries
Orion Group
About Orion
Products and services
Partnering and licensing
Investors
Media
Corporate Governance
Contact us
Careers at Orion
Open vacancies
Working at Orion
Students
Career stories
Research
Orion R&D
Research areas
Research for patient well-being
R&D pipeline
Scientific publications
Sustainability
Policies
Management of Sustainability
Sustainability Reports
Patient organisation collaboration
Stories about responsibility
Raising the Bar
Health Professionals
Simdax.com
Dexdor.eu
Wehale.life
Orion Now
Orion Group
Orion Group
Orion's century
1910s
A superstar of Finnish chemistry
It all began with Albin and woodfern
Orion’s milestones in the 1910s
1920s
A tireless promoter of children’s health
One big family
Orion’s milestones in the 1920s
1930s
Finnishness as an advertising asset
PR in the 1930s: Welcome to the Vallila plant!
Orion’s milestones in the 1930s
1940s
A miracle drug amidst the war
Orion relocated
Orion’s milestones in the 1940s
1950s
A legendary school for laboratory assistants
Finns’ favourite ointments
Orion’s milestones in the 1950s
1960s
The man behind the research
An idyllic estate
Orion’s milestones in the 1960s
1970s
How can I help you?
International horizons: rapid tests and Finnishness
Orion’s milestones in the 1970s
1980s
New address: Orionintie 1
“For manly pain” – from drugs to brands
Orion’s milestones in the 1980s
1990s
Joining forces with a competitor
An inhaler that helps asthmatics and the atmosphere
Orion’s milestones in the 1990s
2000s
The long road to market
The last hope for a heart patient
Orion’s milestones in the 2000s
2010s
Pink light to promote girls’ rights
From a mobile phone factory to a pharmaceutical plant
Orion’s milestone in the 2010s
About Orion
Management
Board of Directors
Executive management board
Orion values
Mission and strategy
Partnering and licensing
Partnering opportunities
Alliance and Partner Management Excellence
Products and Services
Prescription drugs and self-care products
Veterinary medicine
Active Pharmaceutical Ingredients
Contract manufacturing
Investors
Orion as an investment
Market reviews
Market reviews 2021
Market reviews 2020
Market reviews 2019
Market reviews 2018
Market reviews 2017
Market reviews 2016
Market reviews 2015
Market reviews 2014
Market reviews 2013
Market reviews 2012
Market reviews 2011
Market reviews 2010
Market reviews 2009
Market reviews 2008
Market reviews 2007
CEO's review
CEO Timo Lappalainen's reviews 2021
CEO Timo Lappalainen's reviews 2020
CEO Timo Lappalainen's reviews 2019
CEO Timo Lappalainen's reviews 2018
CEO Timo Lappalainen's reviews 2017
CEO Timo Lappalainen's reviews 2016
CEO Timo Lappalainen's reviews 2015
CEO Timo Lappalainen's reviews 2014
CEO Timo Lappalainen’s reviews 2013
CEO Timo Lappalainen’s reviews 2012
CEO Timo Lappalainen's reviews 2011
CEO Timo Lappalainen's reviews 2010
CEO Timo Lappalainen’s reviews 2009
CEO Timo Lappalainen’s reviews 2008
CEO's reviews 2007
Financial Information
Key figures
Quarterly figures
Credit programmes
Outlook for 2022
Outlook for 2021
Outlook for 2020
Outlook for 2019
Outlook for 2018
Outlook for 2017
Outlook for 2016
Outlook for 2015
Outlook for 2014
Outlook for 2013
Outlook for 2012
Outlook for 2011
Outlook for 2010
Outlook for 2009
Outlook for 2008
Outlook for 2007
Outlook for 2006
Basis for outlook
Accounting policies
Calculation of key figures
Financial reviews and presentations
Capital Markets Days
Financial Statements
Other events
Orion acquires Inovet's animal health business
Share information
Share capital and shares
Share-related key figures
Treasury shares
Share price
Alternative exchanges monitor
Historical share prices
Total return calculator
Dividends
Analysts
Consensus estimates
Shareholders
Major shareholders by shares
Major shareholders by votes
Ownership structure
Flagging notifications
Insider register
Conversion of shares
Changes in shareholder's contacts
Transactions of managers
Messages to shareholders
Annual General Meetings
AGM 2023
AGM 2022
AGM 2021
AGM 2020
AGM 2019
AGM 2018
AGM 2017
AGM 2016
AGM 2015
AGM 2014
AGM 2013
AGM 2012
AGM 2011
AGM 2010
AGM 2009
AGM 2008
AGM 2007
IR Calendar
Silent period
Archive
Investor Relations
CMD 2021
Media
Stock Exchange Releases
Press Releases
Managers' transactions
Subscribe to releases
Material Bank
Disclosure Policy
Corporate Governance
Corporate Governance
Corporate Governance Statement
AGM
Board of Directors
Activities and duties
Principles Concerning Diversity of the Board of Directors
Board members
Mikael Silvennoinen
Hilpi Rautelin
Kari Jussi Aho
Maziar Mike Doustdar
Ari Lehtoranta
Veli-Matti Mattila
Eija Ronkainen
Karen Lykke Sorensen
Board Committees
Nomination Committee
Authorisations of the Board of Directors
CEO and Executive Management Board
Activities and duties
Introductions of the Executive Management Board members
Liisa Hurme
Satu Ahomäki
Olli Huotari
Juhani Kankaanpää
Jari Karlson
Virve Laitinen
Niclas Lindstedt
Hao Pan
Outi Vaarala
Employee representative Jani Korhonen
Remuneration
Remuneration Report
Remuneration Policy
Share-based incentive plans
Risks and internal control
Strategic risks
Operational risks
Financial risks
Compliance risks
Insider administration
Audit
Articles of Association
Modern Slavery and Human Trafficking Statement
Contact us
Drug safety and product information
Locations and contact persons
Sites and offices
Pharmaceutical manufacturing
Sales offices and representative offices
Animal Health
Fermion
Contact persons
Invoicing addresses
Research
Research
Orion R&D
Orion's R&D Pipeline
Research areas
Research for patient well-being
Living with a diagnosis
Asthma
ALS
Prostate cancer
Breast cancer
Parkinson's disease
Alzheimer's disease
Drug development
Scientific publications
Clinical Research Privacy Statement
Human Data Research Privacy Statement
Orion Research Foundation
Information about the Research Foundation
The Administration of the Research Foundation
Instructions for grant applicant
Instructions for grant recipient
Orion Research Foundation's grants
Frequently asked questions
Contacts
Orion Research Foundation Grants for 2023: apply by 10 September 2022
Sustainability
Sustainability
Management of sustainability
Sustainability Agenda
Patient safety and reliable supply of medications
Environment
Responsibility for Orionees
Business ethics and transparency
Policies
Our approach to corporate responsibility
Code of Conduct
Human Resources Policy
EHS Policy
Quality Policy
Anti-Corruption Policy
Supplier requirements
Pharmaceutical R&D Ethics Policy
Bioethics and Animal Welfare
Using Human Tissues, GMO and Stem Cells
Ethics in the Clinical Research Phases
Ethics in the Marketing Phase
Sustainability Reports
Sustainability Report 2021
Previous reports
Patient organisation collaboration
Healthcare professional collaboration
Stories about responsibility
Raising the Bar
Careers at Orion
Careers at Orion
Open Vacancies
Applying for a job – questions and answers
Working in the pharmaceutical industry
Developing competence at Orion
Building personnel well-being
Career stories
Health Professionals
Stock Exchange Releases
Select year
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
1/25/2023
154,112 Orion Corporation A shares converted into B shares
1/12/2023
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2023 Annual General Meeting
12/28/2022
40,443 Orion Corporation A shares converted into B shares
11/4/2022
Orion Corporation completed share acquisitions
11/4/2022
Orion Corporation: Acquisition of Own Shares 04.11.2022
11/3/2022
Orion Corporation: Acquisition of Own Shares 03.11.2022
11/2/2022
Orion Corporation: Acquisition of Own Shares 02.11.2022
11/1/2022
Orion Corporation: Acquisition of Own Shares 01.11.2022
10/31/2022
Orion Corporation: Acquisition of Own Shares 31.10.2022
10/28/2022
Orion Corporation: Acquisition of Own Shares 28.10.2022
10/27/2022
Orion Corporation: Acquisition of Own Shares 27.10.2022
10/26/2022
ORION CORPORATION: ACQUISITION OF OWN SHARES 26.10.2022
10/26/2022
83,587 Orion Corporation A shares converted into B shares
10/25/2022
Orion Corporation: Acquisition of Own Shares 25.10.2022
10/24/2022
Orion Corporation: Acquisition of Own Shares 24.10.2022
10/21/2022
Orion Corporation: Acquisition of Own Shares 21.10.2022
10/20/2022
Orion Group Interim Report 1–9/2022
10/17/2022
Changes in Orion Group Executive Management Board and new organisational structure as of 1 January 2023
9/20/2022
Change in Orion Group Executive Management Board as of 1 November 2022 – Juhani Kankaanpää appointed as Senior Vice President of Global Operations
9/19/2022
Orion Corporation: Acquisition of Own Shares 19.09.2022
9/19/2022
165,797 Orion Corporation A shares converted into B shares
9/16/2022
ORION CORPORATION: ACQUISITION OF OWN SHARES 16.09.2022
9/15/2022
Orion Corporation: Acquisition of Own Shares 15.09.2022
9/14/2022
ORION CORPORATION: ACQUISITION OF OWN SHARES 14.09.2022
9/13/2022
Orion Corporation: Acquisition of Own Shares 13.09.2022
9/12/2022
Orion Corporation: Acquisition of Own Shares 12.09.2022
9/9/2022
Orion Corporation: Acquisition of Own Shares 09.09.2022
9/8/2022
ORION CORPORATION: ACQUISITION OF OWN SHARES 08.09.2022
9/7/2022
ORION CORPORATION: ACQUISITION OF OWN SHARES 07.09.2022
9/6/2022
Orion Corporation: Acquisition of Own Shares 06.09.2022
9/5/2022
Orion Corporation: Acquisition of Own Shares 05.09.2022
9/2/2022
ORION CORPORATION: ACQUISITION OF OWN SHARES 02.09.2022
9/2/2022
Prosecutor appealed the district court's decision to dismiss the charges pressed against a member of Orion's Board of Directors for a suspected securities market offence
9/1/2022
Orion Corporation: Acquisition of Own Shares 01.09.2022
8/25/2022
Decision by the Board of Directors to acquire own shares
7/15/2022
Orion Group Half-Year Financial Report 1–6/2022
7/15/2022
Orion Corporation's financial reporting and Annual General Meeting in 2023
7/13/2022
Orion upgrades full-year outlook for 2022 following the USD 290 million upfront payment regarding ODM-208 agreement
7/13/2022
Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
6/28/2022
6,214 Orion Corporation A shares converted into B shares
6/15/2022
Orion Acquires Inovet’s Animal Health Business
6/10/2022
Charges pressed by prosecutor against a member of Orion’s Board of Directors for a suspected securities market offence dismissed
5/10/2022
292,451 Orion Corporation A shares converted into B shares
4/29/2022
Composition of the Nomination Committee of Orion Corporation
4/28/2022
CORRECTION: Orion Group Interim Report 1–3/2022
4/28/2022
Orion Group Interim Report 1–3/2022
4/20/2022
Liisa Hurme appointed President and CEO of Orion Corporation as of 1 November 2022
3/23/2022
Orion Corporation: Organising meeting of the Board of Directors
3/23/2022
Decisions taken by Orion Corporation’s Annual General Meeting on 23 March 2022
3/7/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
3/3/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
3/1/2022
Orion Corporation: Transfer of 38,543 own B shares on 1 March 2022
3/1/2022
Orion Group Financial Statement documents 2021, Corporate Governance Statement and Remuneration Report published
2/25/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
2/24/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
2/17/2022
Orion’s collaboration partner Bayer upgrades estimate on Nubeqa®’s peak sales potential
2/17/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
2/11/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
2/10/2022
Orion Corporation: The Board of Directors of Orion Corporation decided on an incentive plan for key persons
2/10/2022
Notice to the Annual General Meeting of Orion Corporation
2/10/2022
Orion Group Financial Statement Release for 2021
2/9/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
2/8/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
2/1/2022
38,220 Orion Corporation A shares converted into B shares
1/27/2022
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
12/10/2021
102,428 Orion Corporation A shares converted into B shares
12/3/2021
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
11/25/2021
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2022 Annual General Meeting
10/20/2021
Orion Group Interim Report 1–9/2021
10/8/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
10/8/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
9/17/2021
Successor plan of the President and CEO of Orion
9/14/2021
90,889 Orion Corporation A shares converted into B shares
7/22/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
7/21/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
7/19/2021
Orion Group Half-Year Financial Report 1-6/2021
7/19/2021
Orion Corporation's financial reporting and Annual General Meeting in 2022
7/16/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
7/15/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
7/8/2021
32,884 Orion Corporation A shares converted into B shares
7/2/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
6/30/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
6/29/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
6/28/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
6/23/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
6/23/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
6/18/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
6/17/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/28/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/27/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/20/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/19/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/17/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/11/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/5/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
5/5/2021
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
4/27/2021
CORRECTION: Composition of the Nomination Committee of Orion Corporation
4/27/2021
Composition of the Nomination Committee of Orion Corporation
4/27/2021
Orion Group Interim Report 1-3/2021
3/25/2021
Orion Corporation: Organising meeting of the Board of Directors
3/25/2021
Decisions taken by Orion Corporation’s Annual General Meeting on 25 March 2021
3/3/2021
Change to the Notice of Orion Corporation’s Annual General Meeting
3/2/2021
Orion Group Financial Statement documents 2020, Corporate Governance Statement and Remuneration Report published
3/1/2021
Orion Corporation: Transfer of 99,768 own B shares on 1 March 2021
2/9/2021
Notice to the Annual General Meeting of Orion Corporation
2/9/2021
Orion Group Financial Statement Release for 2020
2/2/2021
83,386 Orion Corporation A shares converted into B shares
1/12/2021
Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation
12/18/2020
8,242 Orion Corporation A shares converted into B shares
10/29/2020
Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion
10/21/2020
Composition of the Nomination Committee of Orion Corporation
10/21/2020
Orion Group Interim Report 1-9/2020
10/19/2020
Orion upgrades full-year outlook for 2020
10/19/2020
120,939 Orion Corporation A shares converted into B shares
7/28/2020
Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpoints
7/17/2020
Orion Group Half-Year Financial Report 1-6/2020
7/17/2020
Orion Corporation's financial reporting and Annual General Meeting in 2021
7/14/2020
191,501 Orion Corporation A shares converted into B shares
7/8/2020
Orion upgrades full-year outlook for 2020
6/25/2020
The cancellation of Orion Corporation shares entered in the Trade Register
6/15/2020
Orion Corporation has decided on cancellation of shares on the joint account
6/2/2020
520,144 Orion Corporation A shares converted into B shares
5/25/2020
Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and Development
5/6/2020
Orion Corporation: Organising meeting of the Board of Directors
5/6/2020
Orion Corporation: Decisions by the AGM on 6 May 2020
4/28/2020
Orion Corporation: Change in Orion Group Executive Management Board as of 1 May 2020
4/28/2020
Orion Group Interim Report 1-3/2020
4/24/2020
Orion upgrades full-year outlook for 2020
4/17/2020
Orion has been notified by the largest shareholders by votes that at the AGM to be held on 6 May 2020 they will support the proposals that are in the notice to the AGM
4/14/2020
Notice to the Annual General Meeting of Orion Corporation
4/7/2020
79,971 Orion Corporation A shares converted into B shares
3/19/2020
Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date
3/5/2020
Orion Corporation: Change in Orion Group Executive Management Board as of 1 April 2020
3/2/2020
Orion Corporation: Transfer of 94,317 own B shares on 2 March 2020
3/2/2020
Orion Group Financial Statement documents 2019 and Corporate Governance Statement published
2/5/2020
CORRECTION: Orion Group Financial Statement Release for 2019 - wrong dividend payment date
2/5/2020
Notice to the Annual General Meeting of Orion Corporation
2/5/2020
Orion Group Financial Statement Release for 2019
1/22/2020
Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation
1/21/2020
228,223 Orion Corporation A shares converted into B shares
12/18/2019
33,944 Orion Corporation A shares converted into B shares
11/28/2019
Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%
11/28/2019
192,172 Orion Corporation A shares converted into B shares
11/4/2019
125,000 Orion Corporation A shares converted into B shares
10/28/2019
Composition of the Nomination Committee of Orion Corporation
10/23/2019
Orion Group Interim Report 1–9/2019
9/2/2019
135,000 Orion Corporation A shares converted into B shares
7/17/2019
Orion Group Half-Year Financial Report January–June 2019
7/17/2019
Orion Corporation's financial reporting and Annual General Meeting in 2020
6/19/2019
1,767 Orion Corporation A shares converted into B shares
6/11/2019
Change in Orion Corporation's holding of treasury shares
5/13/2019
Orion Corporation completed share acquisitions
5/13/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 13.05.2019
5/10/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 10.05.2019
5/9/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 09.05.2019
5/8/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 08.05.2019
5/7/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 07.05.2019
5/7/2019
CORRECTION: ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019
5/6/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019
5/3/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 03.05.2019
5/2/2019
ORION CORPORATION: ACQUISITION OF OWN SHARES 02.05.2019
4/25/2019
Decision by the Board of Directors to acquire own shares
4/25/2019
Orion Group Interim Report January-March 2019
4/16/2019
297,000 Orion Corporation A shares converted into B shares
3/26/2019
Orion Corporation: Organising meeting of the Board of Directors
3/26/2019
Orion Corporation: Decisions by the AGM on 26 March 2019
3/4/2019
Orion Group Financial Statement documents 2018 and Corporate Governance Statement published
3/1/2019
Orion Corporation: Transfer of 47,279 own B shares on 1 March 2019
2/6/2019
The Board of Directors of Orion Corporation decided on an incentive plan for key persons
2/6/2019
Notice to the Annual General Meeting of Orion Corporation
2/6/2019
Orion Group Financial Statement Release for 2018
1/9/2019
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation
10/30/2018
Composition of the Nomination Committee of Orion Corporation
10/24/2018
Orion Group Interim Report January-September 2018
10/24/2018
Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met
9/19/2018
Changes in responsibility areas of the Orion Group Executive Management Board
7/18/2018
Orion Group Half-Year Financial Report January-June 2018
7/18/2018
Orion Corporation's financial reporting and Annual General Meeting in 2019
4/24/2018
Orion Group Interim Report January-March 2018
4/21/2018
Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook
3/20/2018
Orion Corporation: Organising meeting of the Board of Directors
3/20/2018
Orion Corporation: Decisions by the AGM on 20 March 2018
3/1/2018
Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018
2/26/2018
Orion Group Financial Statement documents 2017 and Corporate Governance Statement published
2/7/2018
Notice to the annual general meeting of Orion Corporation
2/7/2018
Orion Group Financial Statement Release for 2017
1/24/2018
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2018 AGM of Orion Corporation
1/23/2018
Orion to investigate possible sale of Orion Diagnostica
10/26/2017
Composition of the Nomination Committee of Orion Corporation
10/26/2017
Orion Group Interim Report January-September 2017
8/1/2017
146,000 Orion Corporation A shares converted into B shares
7/19/2017
Orion Group Half-Year Financial Report January-June 2017
7/19/2017
Orion Corporation's financial reporting and Annual General Meeting in 2018
6/19/2017
187,133 Orion Corporation A shares converted into B shares
6/1/2017
248,549 Orion Corporation A shares converted into B shares
4/26/2017
Orion Group Interim Report January-March 2017
4/19/2017
398,245 Orion Corporation A shares converted into B shares
4/12/2017
Publishing of Orion Corporation's Interim Report for January-March 2017 on 26 April 2017
4/6/2017
Amendment to Sections 5 and 9(1) of the Articles of Association of Orion Corporation entered in the Trade Register
3/22/2017
Orion Corporation: Organising meeting of the Board of Directors
3/22/2017
Orion Corporation: Decisions by the AGM on 22 March 2017
3/1/2017
Orion Corporation: Transfer of 107,965 own B-shares on 1 March 2017
2/27/2017
Orion Group Financial Statement documents 2016 and Corporate Governance Statement published
2/13/2017
Change in Orion Group Executive Management Board as of 21 February 2017
2/8/2017
Notice to the annual general meeting of Orion Corporation
2/8/2017
Orion Group Financial Statement Release for 2016
1/27/2017
193,881 Orion Corporation A shares converted into B shares
1/25/2017
Publishing of Orion Corporation's Financial Statement Release for 2016 on 8 February 2017
1/24/2017
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2017 AGM of Orion Corporation
12/22/2016
87,000 Orion Corporation A shares converted into B shares
11/18/2016
100,000 Orion Corporation A shares converted into B shares
10/25/2016
Orion Group Interim Report January-September 2016
10/11/2016
Publishing of Orion Corporation's Interim Report for January-September 2016 on 25 October 2016
10/5/2016
100,000 Orion Corporation A shares converted into B shares
9/7/2016
Composition of the Nomination Committee of Orion Corporation
7/19/2016
Orion Group Half-Yearly Report January-June 2016
7/19/2016
Orion Corporation's publication schedules for financial reporting in 2017
7/14/2016
100,000 Orion Corporation A shares converted into B shares
7/5/2016
Publishing of Orion Corporation's Half-Yearly Report for January-June 2016 on 19 July 2016
6/15/2016
Orion Corporation completed share acquisitions
6/15/2016
Orion Corporation: Acquisition of own shares 15 June 2016
6/15/2016
Orion upgrades full-year outlook for 2016
6/14/2016
Orion Corporation: Acquisition of own shares 14 June 2016
6/13/2016
Orion Corporation: Acquisition of own shares 13 June 2016
6/10/2016
Orion Corporation: Acquisition of own shares 10 June 2016
6/9/2016
Orion Corporation: Acquisition of own shares 9 June 2016
6/8/2016
Orion Corporation: Acquisition of own shares 8 June 2016
6/7/2016
Orion Corporation: Acquisition of own shares 7 June 2016
6/6/2016
Orion Corporation: Acquisition of own shares 6 June 2016
6/3/2016
Orion Corporation: Acquisition of own shares 3 June 2016
6/3/2016
Orion and Bayer expand clinical development program for ODM-201 (BAY-1841788) and initiate a new phase III study ARASENS in patients with metastatic hormone-sensitive prostate cancer
5/13/2016
100,000 Orion Corporation A shares converted into B shares
4/27/2016
Decision by the Board of Directors to acquire own shares
4/27/2016
Orion Group Interim Report January-March 2016
4/13/2016
Publishing of Orion Corporation's Interim Report for January-March 2016 on 27 April 2016
4/12/2016
125,000 Orion Corporation A shares converted into B shares
3/22/2016
Orion Corporation: Organising meeting of the Board of Directors
3/22/2016
Orion Corporation: Decisions by the AGM on 22 March 2016
3/1/2016
Orion Corporation: Transfer of 144,350 own B-shares on 1 March 2016
2/29/2016
Orion Group Financial Statement documents 2015 and Corporate Governance Statement published
2/2/2016
The Board of Directors of Orion Corporation decided on an incentive plan for key persons
2/2/2016
Notice to the Annual General Meeting of Orion Corporation
2/2/2016
Orion Group Financial Statement Release for 2015
1/27/2016
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2016 AGM of Orion Corporation
1/19/2016
Publishing of Orion Corporation's Financial Statement Release for 2015 on 2 February 2016
12/9/2015
135,000 Orion Corporation A shares converted into B shares
10/29/2015
Composition of the Nomination Committee of Orion Corporation
10/27/2015
Orion Group Interim Report January-September 2015
10/13/2015
Publishing of Orion Corporation's Interim Report for January-September 2015 on 27 October 2015
10/8/2015
150,000 Orion Corporation A shares converted into B shares
9/24/2015
234,620 Orion Corporation A shares converted into B shares
8/13/2015
200,000 Orion Corporation A shares converted into B shares
7/28/2015
Orion Group Interim Report January-June 2015
7/28/2015
Orion Corporation's publication schedules for financial reporting in 2016
7/14/2015
Publishing of Orion Corporation's Interim Report for January-June 2015 on 28 July 2015
7/9/2015
Orion upgrades full-year outlook for 2015
6/15/2015
229,000 Orion Corporation A shares converted into B shares
5/18/2015
357,560 Orion Corporation A shares converted into B shares
4/29/2015
Orion Group Interim Report January-March 2015
4/27/2015
200,647 Orion Corporation A shares converted into B shares
4/24/2015
Orion upgrades full-year outlook for 2015
4/16/2015
Publishing of Orion Corporation's Interim Report for January-March 2015 on 29 April 2015
3/24/2015
Orion Corporation: Organising meeting of the Board of Directors
3/24/2015
Orion Corporation: Decisions by the AGM on 24 March 2015
3/2/2015
Orion Corporation: Transfer of 141,949 own B-shares on 2 March 2015
3/2/2015
Orion Group Financial Statement documents 2014 and Corporate Governance Statement published
2/4/2015
Notice to the Annual General Meeting of Orion Corporation
2/4/2015
Orion Group Financial Statement Release for 2014
1/27/2015
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2015 AGM of Orion Corporation
1/23/2015
Publishing of Orion Corporation's Financial Statement Release for 2014 on 4 February 2015
12/16/2014
200,000 Orion Corporation A shares converted into B shares
11/21/2014
6,335 Orion A shares converted into B shares
10/22/2014
Composition of the Nomination Committee of Orion Corporation
10/21/2014
Orion Group Interim Report January-September 2014
10/15/2014
180,000 Orion A shares converted into B shares
10/8/2014
Publishing of Orion Corporation's Interim Report for January-September 2014 on 21 October 2014
10/3/2014
163,500 Orion A shares converted into B shares
9/24/2014
Disclosure Under Chapter 9 Section 10
9/22/2014
Orion announces amended settlement agreement over the proprietary drug Precedex®
9/15/2014
100,000 Orion A shares converted into B shares
9/4/2014
310,000 Orion A-shares converted into B-shares
7/29/2014
Orion Group Interim Report January-June 2014
7/29/2014
Orion Corporation's publication schedules for financial reporting in 2015
7/16/2014
Publishing of Orion Corporation's Interim Report for January-June 2014 on 29 July 2014
7/4/2014
150,000 Orion A-shares converted into B-shares
6/13/2014
200,000 Orion A-shares converted into B-shares
6/2/2014
Orion and Bayer enter global agreement for development and commercialization of novel prostate cancer treatment - Orion upgrades full-year outlook for 2014
4/29/2014
Orion Group Interim Report January-March 2014
4/22/2014
Publishing of Orion Corporation's Interim Report for January-March 2014 on 29 April 2014
4/15/2014
300,000 Orion A-shares converted into B-shares
4/14/2014
Orion receives first marketing authorisations for Bufomix Easyhaler® product
4/9/2014
Amendment of Section 12 of Articles of Association of Orion Corporation entered in the Trade Register
3/25/2014
Orion Corporation: Organising meeting of the Board of Directors
3/25/2014
Orion Corporation: Decisions by the AGM on 25 March 2014
3/3/2014
Orion Oyj : Transfer of 119,326 own B-shares on 3 March 2014
3/3/2014
Orion Group Financial Statement documents 2013 and Corporate Governance Statement published
2/4/2014
Notice to the Annual General Meeting of Orion Corporation
2/4/2014
Orion Group Financial Statement Release for 2013
1/30/2014
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2014 AGM of Orion Corporation
1/22/2014
Publishing of Orion Corporation's Financial Statement Release for 2013 on 4 February 2014
12/19/2013
Orion Corporation signs license agreement with Janssen Pharmaceuticals, Inc. for the development and commercialization of its novel treatment for Alzheimer's disease
12/11/2013
Orion Corporation completed share acquisitions
12/11/2013
Orion Corporation: SHARE REPURCHASE December 11, 2013
12/10/2013
Orion Corporation: SHARE REPURCHASE December 10, 2013
12/9/2013
Orion Oyj: SHARE REPURCHASE December 9, 2013
12/5/2013
Orion Corporation: SHARE REPURCHASE December 5, 2013
12/5/2013
Orion settles patent dispute over the proprietary drug Precedex®
12/4/2013
Orion Corporation: SHARE REPURCHASE December 4, 2013
12/3/2013
Orion Corporation: SHARE REPURCHASE December 3, 2013
12/2/2013
Orion Corporation: SHARE REPURCHASE December 2, 2013
11/29/2013
Orion Corporation: SHARE REPURCHASE November 29, 2013
11/28/2013
Orion Corporation: SHARE REPURCHASE November 28, 2013
11/27/2013
Orion Corporation: SHARE REPURCHASE November 27, 2013
11/26/2013
Orion Corporation: SHARE REPURCHASE November 26, 2013
11/25/2013
Orion Corporation: SHARE REPURCHASE November 25, 2013
11/22/2013
Orion Corporation: SHARE REPURCHASE November 22, 2013
11/19/2013
Change in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014
10/25/2013
150,000 Orion A-shares converted into B-shares
10/22/2013
Composition of the Nomination Committee of Orion Corporation
10/22/2013
Orion Group Interim Report January-September 2013
10/21/2013
Orion and Hospira have signed a license agreement to continue the collaboration with Precedex®
10/8/2013
Publishing of Orion Corporation's Interim Report for January-September 2013 on 22 October 2013
8/15/2013
100,000 Orion A-shares converted into B-shares
7/30/2013
Orion Group Interim Report January-June 2013
7/30/2013
Orion Corporation's publication schedules for financial reporting in 2014
7/25/2013
Orion and Mylan settle patent dispute over the proprietary drug Stalevo®
7/16/2013
Publishing of Orion Corporation's Interim Report for January-June 2013 on 30 July 2013
6/19/2013
37,502 Orion A-shares converted into B-shares
6/11/2013
Listing prospectus for Orion Corporation's EUR 150 million bond available
6/4/2013
Orion Corporation issues a EUR 150 million domestic bond on 11 June 2013
6/3/2013
Orion Diagnostica's statutory co-operation negotiations completed
5/20/2013
Orion Corporation is preparing to issue a bond
5/20/2013
225,000 Orion A-shares converted into B-shares
4/23/2013
Decision by the Board of Directors to acquire own shares
4/23/2013
Orion Group Interim Report January-March 2013
4/19/2013
700,000 Orion A-shares converted into B-shares
4/10/2013
Orion Diagnostica proposes co-operation negotiations on streamlining its operations and reducing no more than 80 employees in Finland
4/9/2013
Orion invites analysts and media to Q1 conference on Tuesday 23 April 2013
3/21/2013
Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family
3/19/2013
Orion Corporation: Organising meeting of the Board of Directors
3/19/2013
Orion Corporation: Decisions by the AGM on 19 March 2013
3/1/2013
Transfer of 137,000 own B-shares on 1 March 2013
2/26/2013
Orion Group Annual Report 2012 and Corporate Governance Statement published
2/5/2013
The Board of Directors of Orion Corporation decided on an incentive plan for key persons
2/5/2013
Notice to the Annual General Meeting of Orion Corporation
2/5/2013
Orion Group Financial Statement Release for 2012
1/22/2013
Orion invites analysts and media to Financial Statement Release conference on Tuesday 5 February 2013
1/21/2013
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2013 AGM of Orion Corporation
1/21/2013
Annual Summary of Stock Exchange Releases published in 2012
1/16/2013
31,900 Orion A-shares converted into B-shares
12/20/2012
Orion and Mylan settle patent dispute over the proprietary drug Comtan®
12/20/2012
203,000 Orion A-shares converted into B-shares
11/30/2012
Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family
11/19/2012
823,000 Orion A-shares converted into B-shares
10/23/2012
Composition of the Nomination Committee of Orion Corporation
10/23/2012
Orion Group Interim Report January-September 2012
10/9/2012
Orion upgrades full-year outlook for 2012
10/9/2012
Orion invites analysts and media to Q3 news conference on Tuesday 23 October 2012
9/12/2012
200,000 Orion A-shares converted into B-shares
9/5/2012
Orion Corporation: Correction to the English version of the stock exchange release
9/5/2012
Disclosure Under Chapter 2 Section 10
7/31/2012
Orion Group Interim Report January-June 2012
7/31/2012
Orion Corporation's publication schedules for financial reporting in 2013
7/16/2012
Orion invites analysts and media to Q2 news conference on Tuesday 31 July 2012
7/5/2012
200,000 Orion A-shares converted into B-shares
7/3/2012
Orion upgrades full-year outlook for 2012
5/1/2012
U.S. District Court gives decision on Precedex® patent litigation
4/26/2012
Orion sues Mylan in the U.S. to enforce its U.S. patents covering the proprietary drug Stalevo®
4/24/2012
Orion Group Interim Report January-March 2012
4/10/2012
Orion invites analysts and media to Q1 news conference on Tuesday 24 April 2012
4/10/2012
Orion Corporation: 300,000 Orion A-shares converted into B-shares
3/26/2012
Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version of Orion's proprietary drug Stalevo® in the United States
3/20/2012
Orion Oyj : Orion Corporation: Organising meeting of the Board of Directors
3/20/2012
Orion Oyj : Decisions by the AGM on 20 March 2012
3/12/2012
Orion Corporation: Transfer of 87,763 own B-shares on 12 March 2012
3/6/2012
Orion Group Annual Report 2011 published
2/7/2012
Notice to the Annual General Meeting of Orion Corporation
2/7/2012
Orion Group Financial Statement Release for 2011
2/7/2012
Orion continues development of inhalable budesonide-formoterol combined formulation
1/30/2012
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2012 AGM of Orion Corporation
1/20/2012
Orion Corporation: Annual Summary of Stock Exchange Releases published in 2011
1/20/2012
Orion invites analysts and media to Financial Statement Release conference on Tuesday 7 February 2012
12/20/2011
Orion Corporation: 201,000 Orion A-shares converted into B-shares
11/7/2011
Disclosure Under Chapter 2 Section 10
11/7/2011
53,428 Orion A-shares converted into B-shares
10/25/2011
Change in Orion Group Executive Management Board as of 1 January 2012
10/25/2011
Orion Group Interim Report January-September 2011
10/11/2011
Orion invites analysts and media to Q3 news conference on Tuesday 25 October 2011
9/26/2011
Disclosure Under Chapter 2 Section 10
9/23/2011
400,000 Orion A-shares converted into B-shares
9/21/2011
Composition of the Nomination Committee of Orion Corporation
9/21/2011
Orion receives European marketing authorisation for dexdor®
9/14/2011
400,000 Orion A-shares converted into B-shares
8/19/2011
136,231 Orion A-shares converted into B-shares
8/2/2011
Orion Group Interim Report January-June 2011
8/2/2011
Orion Corporation's publication schedules for financial reporting in 2012
7/22/2011
Orion receives positive CHMP opinion for new intensive care sedative, dexdor® (dexmedetomidine)
7/18/2011
Orion invites analysts and media to Q2 news conference on Tuesday 2 August 2011
6/22/2011
100,000 Orion A-shares converted into B-shares
6/9/2011
628,914 Orion A-shares converted into B-shares
5/5/2011
173,500 Orion A-shares converted into B-shares
4/27/2011
Orion Group Interim Report January-March 2011
4/20/2011
397,408 Orion A-shares converted into B-shares
4/18/2011
Orion invites analysts and media to Q1 news conference on Wednesday 27 April 2011
4/13/2011
Orion upgrades full-year outlook for 2011
3/31/2011
Orion Corporation: Organising meeting of the Board of Directors
3/31/2011
Orion Corporation: Decisions by the AGM on 31 March 2011
3/31/2011
President and CEO Timo Lappalainen today at Annual General Meeting of Orion Corporation: Orion's sales developed well in early 2011
3/9/2011
Orion Group Annual Report 2010 published
3/1/2011
Orion Corporation: Transfer of 102,900 own B-shares
2/9/2011
Notice to the Annual General Meeting of Orion Corporation
2/9/2011
Orion Group Financial Statement Release for 2010
1/31/2011
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2011 AGM of Orion Corporation
1/24/2011
Orion sues Mylan in the U.S. to enforce its U.S. patent covering the proprietary drug Comtan®
1/20/2011
Orion invites analysts and media to Financial Statement Release conference on Wednesday 9 February 2011
1/19/2011
Annual Summary of Stock Exchange Releases published in 2010
1/14/2011
79,866 Orion A-shares converted into B-shares
12/15/2010
Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version of Orion's proprietary drug Comtan® (entacapone) in the United States
11/12/2010
321,946 Orion A-shares converted into B-shares
11/1/2010
Composition of the Nomination Committee of Orion Corporation
10/26/2010
Orion Group Interim Report January-September 2010
10/20/2010
European Medicines Agency has initiated the review of Orion´s dexmedetomidine marketing authorisation application
10/15/2010
Disclosure Under Chapter 2 Section 9
10/11/2010
Orion invites analysts and media to Q3 news conference on Tuesday 26 October 2010
9/24/2010
Change in Orion Group Executive Management Board as of 1 Jan 2011
9/1/2010
Orion: Change in the holding of own shares
8/20/2010
Orion comments on today's FDA release on safety review of Stalevo®
8/13/2010
435,019 Orion A-shares converted into B-shares
8/10/2010
Orion Group Interim Report January-June 2010
8/10/2010
Orion Corporation's publication schedules for financial reporting in 2011
7/19/2010
Orion invites analysts and media to Q2 news conference on Tuesday 10 August 2010
6/22/2010
Orion and Sun settle patent dispute
6/17/2010
20,138 Orion A-shares converted into B-shares
6/15/2010
Composition of R&D Committee as of 15 June 2010
6/14/2010
Orion upgrades full-year outlook for 2010
6/1/2010
1,100,000 Orion A-shares converted into B-shares
5/18/2010
Decision by the Board of Directors to repurchase own shares
5/18/2010
Change in Orion Group Executive Management Board as of 1 Oct 2010
4/30/2010
1,700,000 Orion A-shares converted into B-shares
4/27/2010
Orion Group Interim Report January-March 2010
4/20/2010
Dexmedetomidine Phase III program completed with positive results
4/15/2010
Orion invites analysts and media to Q1 news conference on Tuesday 27 April 2010
4/8/2010
Amendment of Section 12 of Articles of Association entered in the Trade Register
4/1/2010
Orion comments on FDA release on Stalevo
3/24/2010
Orion Corporation: Matti Kavetvuo Vice Chairman of the Board of Directors. Compositions of Board committees
3/24/2010
Orion Corporation: Decisions by the AGM on 24 March 2010
3/11/2010
Orion Corporation: Member of the Board of Directors of Orion Corporation Leena Palotie passed away
3/2/2010
Orion Group Annual Report 2009 published
3/1/2010
Orion Corporation: Transfer of 65,606 own B-shares on 1 March 2010
2/18/2010
The Board of Directors of Orion Corporation decided on an incentive plan for key persons
2/9/2010
Notice to the Annual General Meeting of Orion Corporation
2/9/2010
Orion Group Financial Statement Release of 2009
2/1/2010
Orion invites analysts and media to Financial Statement Release conference on 9 February 2010
1/20/2010
Annual Summary of Stock Exchange Releases published in 2009
1/19/2010
ORION CORPORATION: Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2010 AGM of Orion Corporation, 19 Jan 2010
1/4/2010
200,000 Orion A-shares converted into B-shares
12/4/2009
Orion clarifies information emanating from Capital Markets Day
11/27/2009
100,000 Orion A-shares converted into B-shares
10/26/2009
Orion Group Interim Report January-September 2009
10/26/2009
Orion Corporation's publication schedules for financial reporting in 2010
10/21/2009
Orion withdraws US application for extending the indication of Stalevo®
10/6/2009
Orion invites analysts and media to Q3 news conference on Monday 26 October 2009
9/21/2009
Composition of the Nomination Committee of Orion Corporation
9/4/2009
Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex®
8/7/2009
Orion: Correction to English version of Interim Report 1-6/2009
8/7/2009
Orion Group Interim Report January-June 2009
7/31/2009
Orion comments on ANDA filed by Sandoz Inc. for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine hydrochloride 100 mcg base/ml ) in the United States
6/10/2009
Orion invites analysts and media to Q2 news conference on Friday 7 August 2009
5/6/2009
Orion reacquires rights for i.v. levosimendan (Simdax®)
4/29/2009
Orion and Wockhardt settle patent dispute
4/27/2009
Orion Group Interim Report 1-3/2009
4/20/2009
Orion invites to a Q1 news conference on Monday 27 April 2009
4/14/2009
Amendments to Orion's Articles of Association entered in the Trade Register
3/23/2009
Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees
3/23/2009
Orion Corporation: Decisions by the AGM on 23 March 2009
3/6/2009
Orion withdraws EU application for extending the indication of Stalevo®
3/5/2009
Orion Corporation: Transfer of 44,806 own B-shares
3/4/2009
Orion Group Annual Report 2008 published
2/24/2009
Orion: Primary objective of STRIDE-PD study was not achieved
2/6/2009
Matters to be handled at the AGM of Orion Corporation on 23 March 2009
2/6/2009
Orion Group Financial Review of 2008
1/28/2009
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2009 AGM of Orion Corporation
1/16/2009
Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2008
1/15/2009
Orion sues Wockhardt USA LLC and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®
1/7/2009
Orion's statutory negotiations completed. Personnel to be reduced by about 205 in Finland
12/11/2008
Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® (25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States
12/8/2008
Orion sues Wockhardt USA, Inc. and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®
11/19/2008
Orion to renew operational model of pharmaceutical R&D. Negotiation proposal on reduction of up to 300 employees in Finland
11/12/2008
Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan®
11/3/2008
Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States
10/29/2008
Composition of the Nomination Committee of Orion Corporation
10/28/2008
Orion Corporation's publication schedules for financial reporting in 2009
10/28/2008
Orion Group Interim Report 1-9/2008
10/7/2008
Orion comments on new ANDA by Sun Pharma Global, Inc. for generic entacapone (Orion's proprietary drug Comtan®) in the United States
9/12/2008
Orion updates progress with dexmedetomidine trials
8/5/2008
Orion Group Interim Report 1-6/2008
7/23/2008
Orion Corporation publishes Interim Report Q2/2008 on 5 August 2008
5/9/2008
Orion has decided not to continue the development of a new COMT inhibitor candidate
4/25/2008
Orion Group Interim Report 1-3/2008
4/15/2008
Orion seeking broader indication for Stalevo
3/25/2008
Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees
3/25/2008
Orion Corporation: Decisions by the AGM on 25 March 2008
2/28/2008
Orion Group Annual Report 2007 published
2/25/2008
ORION OYJ: GTx ANNOUNCED PHASE III CLINICAL DATA FOR TOREMIFENE CITRATE 80 mg
2/7/2008
Orion sues Sun Pharmaceuticals in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo®
2/7/2008
Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2007
2/7/2008
Matters to be handled at Orion's AGM on 25 March 2008
2/7/2008
Orion Group Financial Review of 2007
1/30/2008
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation
1/24/2008
Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease
1/2/2008
Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo® in the United States
11/27/2007
Announcement by Orion Corporation in accordance with section 10 of chapter 2 of the Finnish Securities Market Act
11/15/2007
Appointments into Orion's Executive Management Board as of 1 January 2008
11/13/2007
Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo®
10/24/2007
Composition of the Nomination Committee of Orion Corporation
10/24/2007
Orion Corporation's publication schedules for financial reporting in 2008
10/24/2007
Orion Group Interim Report 1-9/2007
10/1/2007
Orion comments on ANDA filing of generic versions of Orion's proprietary drug Stalevo® in the United States
9/13/2007
Orion sues generic drug companies in the U.S. to enforce patents for entacapone (Orion's proprietary drug Comtan®)
9/11/2007
New President and CEO for Orion Corporation as of 1 January 2008
8/13/2007
Orion comments on ANDA filing of generic entacapone (Orion's proprietary drug Comtan®) in the United States
8/6/2007
Decision of the Board of Directors of Orion on repurchasing own shares
8/6/2007
Orion Group Interim Report 1-6/2007
4/25/2007
Orion Group Interim Report 1-3/2007
4/25/2007
Orion's partner discontinues development of levosimendan (Simdax) in the US
4/2/2007
Jukka Ylppö Vice Chairman of the Board of Directors of Orion Corporation. Compositions of Board committees
4/2/2007
Decisions by the AGM of Orion Corporation on 2 April 2007
3/8/2007
Amendment to the Annual Report 2006 of Orion Corporation concerning holdings of Board members
3/1/2007
Orion Group Annual Report 2006 published
2/6/2007
Matters to be handled at Orion's AGM on 2 April 2007
2/6/2007
Orion updates progress with Simdax (i.v. levosimendan):
2/6/2007
Orion Group Financial Review (proforma) 1-12/2006
2/6/2007
Bulletin of Orion Corporation Financial Statements for 1 July - 31 December 2006
1/29/2007
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation
1/24/2007
Share-based incentive plan for ca. 30 key persons in Orion
1/24/2007
Change in the Executive Management Board of the Orion Group as of 1 February 2007
11/2/2006
Publication schedule for Orion's financial reporting in 2007
11/2/2006
Orion Group Interim Report 7-9/2006 and Financial Review (proforma) 1-9/2006
10/20/2006
Reijo Salonen appointed to Orion's new Senior Vice President, Research and Development
10/16/2006
Composition of the Nomination Committee of Orion Corporation
10/16/2006
Decisions by the shareholders' meeting of the demerged Orion
10/9/2006
Changes in the Executive Management Board of the Orion Group as of 1 November 2006
9/14/2006
Final account of the demerged Orion Corporation
8/31/2006
Change in Orion's R&D management
8/7/2006
Orion to publish its Interim Report for 7-9/2006 already on 2 November 2006
8/7/2006
Orion Group Financial Review 1-6/2006
7/13/2006
Determination of acquisition costs of Orion Corp. and Oriola-KD Corp. shares for Finnish taxation
Orion's century
1910s
A superstar of Finnish chemistry
It all began with Albin and woodfern
Orion’s milestones in the 1910s
1920s
A tireless promoter of children’s health
One big family
Orion’s milestones in the 1920s
1930s
Finnishness as an advertising asset
PR in the 1930s: Welcome to the Vallila plant!
Orion’s milestones in the 1930s
1940s
A miracle drug amidst the war
Orion relocated
Orion’s milestones in the 1940s
1950s
A legendary school for laboratory assistants
Finns’ favourite ointments
Orion’s milestones in the 1950s
1960s
The man behind the research
An idyllic estate
Orion’s milestones in the 1960s
1970s
How can I help you?
International horizons: rapid tests and Finnishness
Orion’s milestones in the 1970s
1980s
New address: Orionintie 1
“For manly pain” – from drugs to brands
Orion’s milestones in the 1980s
1990s
Joining forces with a competitor
An inhaler that helps asthmatics and the atmosphere
Orion’s milestones in the 1990s
2000s
The long road to market
The last hope for a heart patient
Orion’s milestones in the 2000s
2010s
Pink light to promote girls’ rights
From a mobile phone factory to a pharmaceutical plant
Orion’s milestone in the 2010s
About Orion
Management
Board of Directors
Executive management board
Orion values
Mission and strategy
Partnering and licensing
Partnering opportunities
Alliance and Partner Management Excellence
Products and Services
Prescription drugs and self-care products
Veterinary medicine
Active Pharmaceutical Ingredients
Contract manufacturing
Investors
Orion as an investment
Market reviews
Market reviews 2021
Market reviews 2020
Market reviews 2019
Market reviews 2018
Market reviews 2017
Market reviews 2016
Market reviews 2015
Market reviews 2014
Market reviews 2013
Market reviews 2012
Market reviews 2011
Market reviews 2010
Market reviews 2009
Market reviews 2008
Market reviews 2007
CEO's review
CEO Timo Lappalainen's reviews 2021
CEO Timo Lappalainen's reviews 2020
CEO Timo Lappalainen's reviews 2019
CEO Timo Lappalainen's reviews 2018
CEO Timo Lappalainen's reviews 2017
CEO Timo Lappalainen's reviews 2016
CEO Timo Lappalainen's reviews 2015
CEO Timo Lappalainen's reviews 2014
CEO Timo Lappalainen’s reviews 2013
CEO Timo Lappalainen’s reviews 2012
CEO Timo Lappalainen's reviews 2011
CEO Timo Lappalainen's reviews 2010
CEO Timo Lappalainen’s reviews 2009
CEO Timo Lappalainen’s reviews 2008
CEO's reviews 2007
Financial Information
Key figures
Quarterly figures
Credit programmes
Outlook for 2022
Outlook for 2021
Outlook for 2020
Outlook for 2019
Outlook for 2018
Outlook for 2017
Outlook for 2016
Outlook for 2015
Outlook for 2014
Outlook for 2013
Outlook for 2012
Outlook for 2011
Outlook for 2010
Outlook for 2009
Outlook for 2008
Outlook for 2007
Outlook for 2006
Basis for outlook
Accounting policies
Calculation of key figures
Financial reviews and presentations
Capital Markets Days
Financial Statements
Other events
Orion acquires Inovet's animal health business
Share information
Share capital and shares
Share-related key figures
Treasury shares
Share price
Alternative exchanges monitor
Historical share prices
Total return calculator
Dividends
Analysts
Consensus estimates
Shareholders
Major shareholders by shares
Major shareholders by votes
Ownership structure
Flagging notifications
Insider register
Conversion of shares
Changes in shareholder's contacts
Transactions of managers
Messages to shareholders
Annual General Meetings
AGM 2023
AGM 2022
AGM 2021
AGM 2020
AGM 2019
AGM 2018
AGM 2017
AGM 2016
AGM 2015
AGM 2014
AGM 2013
AGM 2012
AGM 2011
AGM 2010
AGM 2009
AGM 2008
AGM 2007
IR Calendar
Silent period
Archive
Investor Relations
CMD 2021
Media
Stock Exchange Releases
Press Releases
Managers' transactions
Subscribe to releases
Material Bank
Disclosure Policy
Corporate Governance
Corporate Governance
Corporate Governance Statement
AGM
Board of Directors
Activities and duties
Principles Concerning Diversity of the Board of Directors
Board members
Mikael Silvennoinen
Hilpi Rautelin
Kari Jussi Aho
Maziar Mike Doustdar
Ari Lehtoranta
Veli-Matti Mattila
Eija Ronkainen
Karen Lykke Sorensen
Board Committees
Nomination Committee
Authorisations of the Board of Directors
CEO and Executive Management Board
Activities and duties
Introductions of the Executive Management Board members
Liisa Hurme
Satu Ahomäki
Olli Huotari
Juhani Kankaanpää
Jari Karlson
Virve Laitinen
Niclas Lindstedt
Hao Pan
Outi Vaarala
Employee representative Jani Korhonen
Remuneration
Remuneration Report
Remuneration Policy
Share-based incentive plans
Risks and internal control
Strategic risks
Operational risks
Financial risks
Compliance risks
Insider administration
Audit
Articles of Association
Modern Slavery and Human Trafficking Statement
Contact us
Drug safety and product information
Locations and contact persons
Sites and offices
Pharmaceutical manufacturing
Sales offices and representative offices
Animal Health
Fermion
Contact persons
Invoicing addresses